anti-cea designer t cells
Cell therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2007 (NCT00429078)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, passive
CEACAM5 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-cea 2nd generation designer t cells
- anti-cea designer t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03818165 | Phase 1 | Feb 1, 2019 | Boston University, Sorrento Therapeutics, Inc. |
| NCT01373047 | Phase 1 | Jun 1, 2011 | Boston University |
| NCT00429078 | Phase 1 | Jul 1, 2007 | Boston University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boston University | Academic/Hospital | 3 | 2 | 1 | 2007 |
| Sorrento Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1